Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jun 15, 2022; 14(6): 1148-1161
Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1148
Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1148
Table 2 Tumor characteristics and surgical quality by surgical approach
| Open (n = 19830) | Laparoscopic (n = 12144) | Robotic (n = 6953) | Total (n = 38927) | P value | |
| Clinical stage | < 0.0011 | ||||
| II | 9286 (46.8%) | 5477 (45.1%) | 2906 (41.8%) | 17669 (45.4%) | |
| III | 10544 (53.2%) | 6667 (54.9%) | 4047 (58.2%) | 21258 (54.6%) | |
| Pathological stage | < 0.0011 | ||||
| 0 | 508 (3.2%) | 323 (3.4%) | 222 (3.9%) | 1053 (3.4%) | |
| 1 | 3801 (23.8%) | 2736 (28.7%) | 1669 (29.6%) | 8206 (26.3%) | |
| 2 | 5416 (33.9%) | 2941 (30.8%) | 1669 (29.6%) | 10026 (32.2%) | |
| 3 | 6107 (38.2%) | 3480 (36.5%) | 2044 (36.3%) | 11631 (37.3%) | |
| 4 | 152 (1.0%) | 57 (0.6%) | 29 (0.5%) | 238 (0.8%) | |
| Chemotherapy sequence | < 0.0011 | ||||
| No chemotherapy | 2031 (10.2%) | 1397 (11.5%) | 459 (6.6%) | 3887 (10.0%) | |
| Chemotherapy after surgery | 1864 (9.4%) | 1210 (10.0%) | 421 (6.1%) | 3495 (9.0%) | |
| Chemotherapy before and after surgery | 5435 (27.4%) | 3691 (30.4%) | 2256 (32.4%) | 11382 (29.2%) | |
| Chemotherapy before surgery | 10481 (52.9%) | 5840 (48.1%) | 3810 (54.8%) | 20131 (51.7%) | |
| Radiation sequence | < 0.0011 | ||||
| No radiation | 2449 (12.3%) | 1713 (14.1%) | 651 (9.4%) | 4813 (12.4%) | |
| Radiation after surgery | 1470 (7.4%) | 911 (7.5%) | 315 (4.5%) | 2696 (6.9%) | |
| Radiation before surgery | 15911 (80.2%) | 9515 (78.4%) | 5987 (86.1%) | 31418 (80.7%) | |
| Total neoadjuvant therapy | 2194 (28.1%) | 1262 (25.1%) | 846 (28.0%) | 4302 (27.1%) | < 0.0011 |
| Surgery type | < 0.0011 | ||||
| TME with sphincter preservation | 12118 (61.1%) | 8633 (71.1%) | 4986 (71.7%) | 25737 (66.1%) | |
| TME without sphincter preservation | 7061 (35.6%) | 2760 (22.7%) | 1927 (27.7%) | 11748 (30.2%) | |
| Conversion to open | 0 (0.0%) | 1760 (14.5%) | 480 (6.9%) | 2240 (11.7%) | < 0.0011 |
| Residual tumor | < 0.0011 | ||||
| R0 | 18012 (91.9%) | 11174 (93.6%) | 6568 (95.1%) | 35754 (93.0%) | |
| R1 | 806 (4.1%) | 413 (3.5%) | 193 (2.8%) | 1412 (3.7%) | |
| R2 | 782 (4.0%) | 352 (2.9%) | 148 (2.1%) | 1282 (3.3%) | |
| Number of lymph nodes examined (mean ± SD) | 14.7 ± 9.7 | 14.8 ± 9.8 | 15.7 ± 9.0 | 14.9 ± 9.6 | < 0.0011 |
| 12 or more lymph nodes examined | 13198 (67.1%) | 8148 (67.7%) | 5088 (73.6%) | 26434 (68.4%) | < 0.0011 |
- Citation: Soriano C, Bahnson HT, Kaplan JA, Lin B, Moonka R, Pham HT, Kennecke HF, Simianu V. Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma. World J Gastrointest Oncol 2022; 14(6): 1148-1161
- URL: https://www.wjgnet.com/1948-5204/full/v14/i6/1148.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i6.1148